Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
anti-CEA CAR-T for CEA-Expressing Liver Metastases or Pancreas Cancer
NCT02850536Phase 1Completed
- Sponsor
- Roger Williams Medical Center
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CEA-CART in liver metastases and pancreatic cancer (PC), sponsored by Roger Williams Medical Center. Primary endpoint: Number of Participants with Adverse Events at 10 weeks. Started Feb 2017; status: completed.
02
Drugs
CEA-CART
03
Conditions
liver metastasespancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02850536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02850536.